

Info Sheet for Technical description

No. 0002

Organization

* Mandatoty fields

Name of Organization*	CellSeed Inc.		
Address, City, States, Zip, Country*	15F(East Wing)Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo 135-0064 Japan		
URL	https://www.cellseed.com/en/		
Brief Descriptions of Organization* (Approx. 100 words)	CellSeed Inc. was founded in 2001 (listed on JASDAQ in 2010) to commercialize a world's first technology of "Cell Sheet Engineering" based on temperature-responsive polymer. By using this technology, CellSeed has developed a variety of intelligent cell cultureware which are used by many researchers actively to conduct R&D activities worldwide. In Japan, three regenerative medicines utilizing our cell sheet engineering technology have been approved by the PMDA. CellSeed is also developing our own regenerative medicine of Allogeneic chondrocyte cell sheet (Clinical Trial Notification for Phase 3 submitted in September 2023) as well. In addition, CellSeed has an in-house CPC capable of manufacturing cell products for clinical use, not only for our ongoing clinical trial but also for providing CDMO service to both domestic and overseas clients.		
Contact address	Name*	Toshihiro Maeda	
	Department* / Position	Board Director	
	E-mail* / TEL	toshihiro.maeda@cellseed.com	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines
- Please see **Sheet [A]**
- ☒ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B)
- Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	Please kindly inform us when the presentation materials are provided to a third party through FIRM.
☐ No	

Filled in by*

Date*

Dandan Song
2025.08.07

Sheet [B] Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. B-0002)

* Mandatoty fields

Title*CDMO**Category***

- | | | |
|--|--|---|
| ☒ Facilities | ☐ Manufacturing equipment | ☐ Inspection equipment |
| ☐ Cells | ☐ Culture medium | ☐ Reagents |
| ☐ Cell banking | ☐ Storage / Container | ☐ Logistics |
| ☒ Cell / Viral vector manufacturing technology | | |

Description*

CellSeed has an in-house Cell Processing Center (CPC) of approximately 763 m², which is approved by the Ministry of Health, Labor, and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA), and is ISO-certified. We have extensive experience in producing various kinds of cell sheets, such as autologous chondrocyte cell sheet, esophageal cell sheet, periodontal ligament cell sheet, mesenchymal stem cell sheet, and others. These cell sheet products are used in Advanced Medical Care B treatments and clinical trials etc. For all cell sheet production, we utilize our innovative cell sheet engineering technology based on temperature responsive polymers.

For autologous chondrocyte cell sheet, cells are isolated from the patient's own cartilage, and for allogeneic chondrocyte cell sheet, cells are extracted from polydactyly tissue. Now we have established an allogeneic chondrocyte cell bank for clinical use and are conducting a Phase 3 clinical trial of allogeneic chondrocyte cell sheet for the treatment of knee osteoarthritis in Japan.

Cell sheet technology is an excellent approach for regenerative medicine due to its advantages such as cell-only composition, easy transplantation by simply placing the sheets on the defect area without suturing, and high engraftment capacity. We provide comprehensive services for cell sheet production, from preliminary development to commercial manufacturing.

Our CDMO services are not limited to cell sheet products. We can offer customized solutions to support the development and expansion of your cell-based products in the Japanese market, leveraging our extensive experience in cell culture and sheet production. In addition, we can provide support for regulatory affairs, including consultation with the PMDA, as needed.

Please feel free to contact us---we are ready to support your business in Japan!

Filled in by*

Dandan Song

Date*

2025.08.07